TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05360251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDL(595nm)
Description: One subject was treated with pulsed dye laser (Vbeam platinum, 595 nm, Candela Corporation): energy dosages of 9-11 J/cm2, pulse durations of 10/20 ms, and spot size of 7 mm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL(DPL)
Description: One subject was treated with IPL(delicate Pulsed Light, Dye-VL, Alma Lasers Corporation): energy dosages of 8.4-10.6 J/cm2, pulse durations of 10/12 ms, and spot size of 10×30 mm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL(M22 590)
Description: One subject was treated with IPL(M22 590, 590-1200nm, Lumenis Limited): energy dosages of 15-18 J/cm2, pulse durations of 3-4 ms, pulse delay of 30-40 ms, and spot size of 15×35 mm.
Study: NCT05275296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracranial stent for wide-necked aneurysms
Description: Intracranial stent for wide-necked aneurysms
Study: NCT05360251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL(M22 vascular)
Description: One subject was treated with IPL(M22 vascular, 530-650nm and 900-1200nm, Lumenis Limited): energy dosages of 9-17 J/cm2, pulse durations of 4-6 ms, pulse delay of 20-40 ms, and spot size of 15×35 mm.
Study: NCT05304442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric]
Description: Single Dose of IV Iron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate 65 mg elemental iron (325 mg tablets)
Description: Once daily by mouth for 42 days
Study: NCT03646058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine, 0.4mg pills, sublingual

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine, 0.4mg pills, sublingual

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills, sublingual, specifically made to mimick buprenorphine pills
Study: NCT04560140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative and Skills-building Intervention
Description: The intervention is grounded in Narrative Theory and Bandura's principles of Self-efficacy and Outcome Expectation. It will consist of eight individual sessions over six months delivered by a facilitator. Participants will be facilitated to narrate their survival experiences and rebuild core life skills.
Study: NCT06136143

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: Autogenous bone graft
Description: The maxillary sinus will be grafted with the autogenous bone graft.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 2: Plenum® Osshp
Description: The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 3: Plenum® Osshp; + i-PRF
Description: The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device associated with i-PRF.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 4: Plenum® Osshp + autogenous bone graft
Description: The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device associated with autogenous bone graft.
Study: NCT04765748

Intervention type: DEVICE
Intervention: Cytosorb
Description: Cytokine filter, which can be used intraoperatively while using a heart lung machine
Study: NCT04953065

Intervention type: OTHER
Intervention: COVID-19 vaccine hesitancy and acceptance survey
Description: Participants will be provided with a COVID-19 vaccine hesitancy and acceptance survey developed by the study team.
Study: NCT06373276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multiplanar balance training exercise with education
Description: 7 minute daily balance training exercises

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: education only
Description: 5 educational broshures
Study: NCT05989438

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orientations for families
Description: Guidance for parents will follow the guide/manual prepared by the researchers, in addition to verbal and video guidance. Once a week a reminder will be sent, and once a month researchers will contact you by phone for guidance.~There will be 3 evaluations with an interval of 4 months. (4 months; 8 months; 12 months).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Professional stimulation more orientations for families.
Description: Each session will last approximately 50 minutes, where the stimuli will be performed in: supine position; Ventral Decubitus; Seated; Four supports, kneeling/semi-kneeling and standing.~If the child no longer uses the posture or it is not an acquisition for the age group in which the baby is, the time will be distributed in order to contemplate the expected acquisitions for the age group in which the baby is. The stimuli will be performed based on the neuropsychomotor development, in order of progression and according to the corrected age of the baby.~The frequency of consultations may vary due to the different degrees of prematurity, and the stipulated initial frequency will vary between 1-8 times a month.~The orientations will also be provided to family members during consultations, and families will also perform stimuli at home according to written, verbal and video guidance.~There will be 3 evaluations with an interval of 4 months. (4 months; 8 months; 12 months).
Study: NCT04578015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Participants in this arm will receive metronidazole 500 mg twice daily, orally for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this arm will receive placebo
Study: NCT06524596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tartaric acid butorphanol
Description: The group received 0.02 mg/kg tartaric acid butorphanol intravenously over 5 minutes, 30 minutes before anaesthesia induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: The group received 0.02 mg/kg normal saline intravenously over 5 minutes, 30 minutes before anaesthesia induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol and remifentanil
Description: Anaesthesia was induced with 2 mg/kg propofol and 0.6 μg/kg remifentanil and maintained with a target-controlled infusion (TCI) of propofol and remifentanil, using the Marsh and Minto models, respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol and remifentanil
Description: Anaesthesia was induced with 2 mg/kg propofol and 0.6 μg/kg remifentanil and maintained with a target-controlled infusion (TCI) of propofol and remifentanil, using the Marsh and Minto models, respectively.
Study: NCT06003439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Program
Description: Behavioral: Virtual Reality Program The VR Program will be pre-installed on Meta Quest 2 headsets, which will be donned by students as a class to experience the intervention for approximately the length of one school class period (approximately 30-40 minutes). Each participant will experience the program once a week for 3 weeks. Participants who missed a week will complete the program by the 4th or 5th week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Program
Description: VR program participants will be able to download a mobile app that complements and reinforces the school-based VR session.
Study: NCT06379828

Intervention type: OTHER
Intervention: Please note that this is an observational study; not applicable
Description: Please note that this is an observational study; not applicable

Intervention type: OTHER
Intervention: Please note that this is an observational study; not applicable
Description: Please note that this is an observational study; not applicable
Study: NCT04848298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: The Mobile Health Arm will receive standard of care including tailored prescription of physical activity as well as the mobile health intervention, which will have the following features:~* Goal setting for frequency and duration of exercise sessions~* Graphic feedback and reinforcement with educational and motivational messages tailored to user's exercise adherence.~* Problem-solving support~* Library with educational tips and information regarding physical exercise.
Study: NCT06204887

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual dynamic activation
Description: The root canals were filled with irrigation solutions. A main gutta percha cone was positioned 1 mm shorter than the working length and 2 mm coronal-apical direction movement was performed at a rate of 100 strokes per minute during 60 s.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic activation
Description: A non-cutting ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) coupled to an ultrasonic device (DTE S6 Led, Guilin Woodpecker Co., Guilin, Guangxi, China) (mode: E, setting: 6) was used according to the manufacturer's recommendations.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser activation
Description: A 2940 nm Er:YAG-laser device (Lightwalker, Fotona, Ljubljana, Slovenia), equipped with a handpiece (H14, Fotona) holding a 8.5 mm long and 600 µm diameter-tapered fiber tip (SWEEPS 600, Fotona) was used for irrigation activation. The device was set to AutoSWEEPS mode with two ultrashort micropulse durations (25 μs) continuously varying at 0.3 W, 20 mJ, 15 Hz settings. The air and water sprays were turned off.
Study: NCT04600921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertugliflozin 5 mg
Description: The subject will receive Ertugliflozin 5mg orally once daily for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 5mg
Description: The subject will receive Placebo 5mg orally daily for 52 weeks.
Study: NCT06487234

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional band
Description: Participants will wear the functional band for 1-hour electroacupuncture stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo band
Description: Participants will wear the nonfunctioning band for 1-hour with no electroacupuncture stimulation
Study: NCT05173974

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Super Poligrip Free
Description: A single application of 1 gram of Super Poligrip Free will be applied topically to oral tissues via the upper denture.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Denture Adhesive 1
Description: A single application of 1 gram of Experimental Denture Adhesive 1 will be applied topically to oral tissues via the upper denture.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Denture Adhesive 2
Description: A single application of 1 gram of Experimental Denture Adhesive 2 will be applied topically to oral tissues via the upper denture.
Study: NCT05887414

Intervention type: OTHER
Intervention: Baseline
Description: Measure Ottawa Decisional Regret at baseline when patients receive a diagnosis of appendicitis.
Study: NCT05779345

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: short implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: short implant placement
Study: NCT05087498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous cord blood mononuclear cells
Description: preterm neonates less than 32 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (2-10×107cells/kg) within 24 hours after birth

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: preterm neonates less than 32 weeks are assigned to receive normal saline within 24 hours after birth
Study: NCT04860115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified pectoralis block (PEC II) and pecto-intercostal fascial plane block (PIFB)
Description: PECS II: Ultrasound guided block involving injection of 20 ml of 0.25% L-bupivacaine with dexmetomidine into an interfascial plane between the serratus anterior muscle and the external intercostal muscles followed by the needle withdrawal into an interfascial plane between the pectoralis major and pectoralis minor muscle where further 10ml will be administered.~PIFB: Ultrasound guided block involving injection of 10 ml of 0.25% L-bupivacaine with dexmetomidine into an iterfascial plane between the pectoralis major and the intercostal muscles approximately 2 cm laterally from the sternum to cover T2 to T6 dermatomes.
Study: NCT04650438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) over the left inferior frontal gyrus (IFG)
Description: MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) over the left inferior frontal gyrus (IFG)
Description: MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.
Study: NCT05887414

Intervention type: OTHER
Intervention: Baseline
Description: Measure Ottawa Decisional Regret at baseline when patients receive a diagnosis of appendicitis.

Intervention type: OTHER
Intervention: 30 Day Follow Up
Description: Measure Ottawa Decisional Regret after 30 days.

Intervention type: OTHER
Intervention: 30 Day Follow Up
Description: Measure Ottawa Decisional Regret after 30 days.
Study: NCT05656495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate intramuscularly
Description: lyophilizate for preparation of solution for intramuscular administration 1 mg 1 time per day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate inhaled
Description: lyophilizate for preparation of solution for inhalation administration 10 mg 1 time per day for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The administration of 'StandardTherapy' drugs was done according to the regimen recommended in the 'COVID-19TreatmentGuidelines'(current version)
Study: NCT05315544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSI pVAD system
Description: The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
Study: NCT05004103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic products application
Description: Female healthy volunteers applied cosmetic products (cleanser and moisturizer) in the morning and afternoon for 1 month. Seven days wash out period will be conducted prior study starts. The evaluation will be conducted before, two weeks after treatment starts, and at the end of the study.
Study: NCT05002452

Intervention type: OTHER
Intervention: Search of factors predicting therapeutic effects and prognosis
Description: There factors are collected in preoperative routine blood examination, preoperative radiological imaging and pathological examination.
Study: NCT05279339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Upper limb exercises using an elastic band.
Study: NCT05022082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest Physiotherapy- Aspiration- Inhaler drugs group
Description: In the intensive care unit where the study was conducted, the patients who have a respiratory disorder and receive supplemental oxygen therapy with non-invasive mechanical ventilation or an oxygen mask are first administered an inhaler drug therapy placed in the physician's order. It is followed by chest physiotherapy and then oropharyngeal and nasopharyngeal aspiration. However, in practice rendered by the researcher, it is suggested that when chest physiotherapy and aspiration are administered in the first place and then followed by an inhaler drug therapy, it might have a more positive impact on the patient's physiologic parameters.

Intervention type: OTHER
Group type: OTHER
Intervention: Chest Physiotherapy- Aspiration- Inhaler drugs group
Description: In the intensive care unit where the study was conducted, the patients who have a respiratory disorder and receive supplemental oxygen therapy with non-invasive mechanical ventilation or an oxygen mask are first administered an inhaler drug therapy placed in the physician's order. It is followed by chest physiotherapy and then oropharyngeal and nasopharyngeal aspiration. However, in practice rendered by the researcher, it is suggested that when chest physiotherapy and aspiration are administered in the first place and then followed by an inhaler drug therapy, it might have a more positive impact on the patient's physiologic parameters.
Study: NCT04650438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) over the left inferior parietal lobule (IPL)
Description: MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) over the left inferior parietal lobule (IPL)
Description: MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.
Study: NCT06167967

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ctDNA methylation
Description: A blood-based circulating tumor DNA methylation assay that uses 6 different methylation markers, SEPT9 region1, SEPT9 region2, BCAT1, IKZF1, BCAN and VAV3.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: This group was treated according to standard procedure
Study: NCT05531006

Intervention type: OTHER
Intervention: retrospective cohort study
Description: retrospective patient file review

Intervention type: OTHER
Intervention: retrospective cohort study
Description: retrospective patient file review
Study: NCT06001190

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: probiotic:Lactobacillus crispatus
Description: We seek to observe that probiotic supplement(arm A) can improve vagina microbiome distribution by comapred to placebo group(arm B) in our study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic:Lactobacillus crispatus
Description: We seek to observe that probiotic supplement(arm A) can improve vagina microbiome distribution by comapred to placebo group(arm B) in our study.
Study: NCT05689879

Intervention type: DRUG
Group type: OTHER
Intervention: STOP arm
Description: TNF-alpha antagonists withdrawal
Study: NCT06380582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature and Airflow combination
Description: 23C 40%Relative Humidity (RH) low airflow, 23C 40%RH high airflow, 35C 40%RH low airflow, 35C 40% high airflow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature and Airflow combination
Description: 23C 40%Relative Humidity (RH) low airflow, 23C 40%RH high airflow, 35C 40%RH low airflow, 35C 40% high airflow
Study: NCT05466734

Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol Tablet 100 mg
Description: Two oral doses (total daily dose of 200 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol Tablet 100 mg
Description: Two oral doses (total daily dose of 200 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: PMR Tablet 135 mg
Description: Single oral dose (total daily dose of 270 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: PMR Tablet 135 mg
Description: Single oral dose (total daily dose of 270 mg)
Study: NCT05843071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal sprays with sea salts
Description: Nasal sprays for nasal congestion and dryness
Study: NCT06507787

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EDIT-B test
Description: EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%.~For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions.~The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: EDIT-B test (without giving result)
Description: EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%.~For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. THE RESULT OF THE TEST WILL NOT BE GIVEN TO THE PARTICIPANT BEFORE THE END OF THE STUDY.~The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact.
Study: NCT06139601

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual single session intervention
Description: A single session, self-paced body empowerment program. The program consists of a single 45-minute self paced, interactive, virtual module.
Study: NCT05017064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy group
Description: The use of intraoral ice pack during root canal treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: No cryotherapy will be used